Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03110562
Title Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Karyopharm Therapeutics Inc

multiple myeloma


Bortezomib + Dexamethasone + Selinexor

Bortezomib + Dexamethasone

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT

No variant requirements are available.